Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
[email protected]+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Author Archives: PharmAust

August 18, Appendix 4G

Financial Reports 2021, News and Announcements 2021By PharmAust18/08/2021

210818_Appendix 4G

August 18, Appendix 4E

Financial Reports 2021, News and Announcements 2021By PharmAust18/08/2021

210818_Appendix 4E

August 3, Epichem Completes OHD Technology Build

News and Announcements 2021By PharmAust03/08/2021

210803_Epichem OHD Technology Update

July 31, Top 20 Shareholders

News and Announcements 2021, Top 20 ShareholdersBy PharmAust01/08/2021

July 31_Top_Holders_Report – 2021-08-03T081238.496

July 30, Virtual Investor Briefing for August 12, 2021

News and Announcements 2021By PharmAust30/07/2021

210730_Virtual Investor Briefing

July 28, Appendix 4C and Quarterly Update

Financial Reports 2021, News and Announcements 2021By PharmAust28/07/2021

210728_Appendix 4C and Q Update

July 26, PharmAust Update on COVID-19 Work

News and Announcements 2021By PharmAust26/07/2021

210726_PAA_Covid_update

July 12, PharmAust and WEHI Investigate Monepantel in HTLV-1 infection

News and Announcements 2021By PharmAust12/07/2021

210712_PharmAust and WEHI Investigate Monepantel in HTLV-1

July 9, PharmAust ANZCVS Science Week Presentation

News and Announcements 2021By PharmAust09/07/2021

210709_Science Week Slides

July 7, Update on Ongoing MPL GMP Tablet Tablet Stability

News and Announcements 2021By PharmAust07/07/2021

210707_GMP Stability Update

←1
23456789
…1011121314…
15161718192021222324252627282930313233343536373839404142434445464748495051
52→
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
24 Jun 2024

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
21 Jun 2024

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065
pharmaust PharmAust @pharmaust ·
21 Jun 2024

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230
Load More

Copyright © 2025 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top